Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Danaher (DHR) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores wo ...

Key Takeaways Labcorp will report third-quarter 2025 results on Oct. 28, before market open.LH's Q3 revenues are estimated at $3.56B, up 8.3%, while EPS is projected to rise 18% to $4.13.LH's Diagnostics and biopharma units may have driven growth through acquisitions and new test launches.Labcorp Holdings Inc. (LH) , or Labcorp, is slated to report its third-quarter 2025 results on Oct. 28, before the market opens.The renowned laboratory service provider reported adjusted earnings of $4.35 in the last repor ...

Core Insights - The Medical Services sector is experiencing rapid transformation due to digital health advancements, value-based care adoption, and a focus on patient-centric solutions [1] - The global healthcare analytics market is projected to grow from $53.12 billion in 2024 to approximately $369.7 billion by 2034, with a CAGR of 21.4% [1] - The U.S. digital health market is expected to increase from about $145.9 billion in 2024 to $396.7 billion by 2028, reflecting a CAGR of 28.4% [4] Industry Overview - The Zacks Medical Services industry includes third-party service providers and caregivers, transitioning from volume-based to value-based care [3] - The resurgence in medical tourism is boosting the sector, necessitating advanced facilities and specialized external service providers [3] Trends Impacting the Industry - Digital Revolution: The increasing availability of unstructured health data and advanced analytics is driving the importance of big data in healthcare, with the global big data in healthcare market expected to grow from $78 billion in 2024 to $540 billion by 2035, at a CAGR of 19.20% [4] - Healthcare Staffing Shortage: A projected shortfall of over 100,000 healthcare workers by 2028, including 73,000 nursing assistants, is expected to elevate labor costs [2][5] - Revival in Nursing Care Market: Employment for nurse anesthetists, nurse midwives, and nurse practitioners is projected to grow 35% from 2024 to 2034, indicating high demand for specialized nursing roles [6] Current Industry Performance - The Medical Services Industry has underperformed compared to the Medical sector and the S&P 500, with a collective loss of 14.9% over the past year [10] - The industry is currently trading at a forward P/E of 15.1X, lower than the S&P 500's 23.7X and the sector's 20.1X [13] Company Highlights - Labcorp Holdings (LH): Expected earnings growth rate of 11.9% for 2025, with a revenue increase of 7.7% from 2024 [19][20] - Charles River Laboratories (CRL): Projected earnings growth rate of 4.9% for 2026, with revenue growth of 2.6% [23][24] - Teladoc Health (TDOC): Anticipated earnings growth rates of 80.1% for 2025 and 26.9% for 2026 [27][28]

Labcorp Holdings (LH) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings ...

Core Insights - Labcorp Holdings Inc. (LH) is a leading global life sciences company with a market cap of $22.9 billion, providing diagnostic, drug development, and laboratory services [1] Financial Performance - LH is expected to report Q3 earnings of $4.12 per share, a 17.7% increase from $3.50 per share in the same quarter last year, having surpassed Wall Street's estimates for the past four quarters [2] - For fiscal 2025, earnings are projected to be $16.30 per share, an 11.9% increase from $14.57 in fiscal 2024, with further growth expected to $17.89 per share in fiscal 2026, representing a 9.8% year-over-year increase [3] Stock Performance - LH stock has increased by 31.9% over the past 52 weeks, outperforming the S&P 500 Index's 17.9% gain and the Health Care Select Sector SPDR Fund's 4.5% decline during the same period [4] - Following the release of strong Q2 2025 results, LH shares rose by 6.9%, with adjusted EPS of $4.35 and revenues of $3.53 billion exceeding consensus estimates [5] Analyst Ratings - The consensus opinion on LH stock is highly optimistic, with a "Strong Buy" rating from 14 out of 18 analysts, while four recommend a "Hold," and the average price target is $296.70, indicating a 6.1% potential upside [6]

Group 1 - Evercore ISI raised the price target on Labcorp (LH) to $305 from $300 while maintaining an Outperform rating on the shares [1] - The firm's survey indicates a positive outlook for preclinical CROs, with rising budgets and declining cancellations [1] - There is stable demand for discovery and toxicology services projected into 2025 and 2026 [1]

Accessibility StatementSkip Navigation BURLINGTON, N.C., Sept. 25, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labc ...

A strong stock as of late has been Labcorp Holdings (LH) . Shares have been marching higher, with the stock up 0.5% over the past month. The stock hit a new 52-week high of $283.47 in the previous session. Labcorp has gained 22.1% since the start of the year compared to the -2% move for the Zacks Medical sector and the -0.6% return for the Zacks Medical Services industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus ...

Core Insights - Labcorp Holdings Inc. is positioned for growth due to the robust performance of its Biopharma Laboratory Services segment and a strong focus on operational efficiency [1][3][5] - The company has experienced a 24.1% stock increase over the past year, outperforming the industry and the S&P 500 [2] - Despite strong financial health and operational initiatives, macroeconomic challenges may limit Labcorp's growth potential [1][9] Financial Performance - Labcorp has a market capitalization of $23.04 billion and an earnings yield of 5.8%, surpassing the industry's 4.2% [2] - The company reported a 11% year-over-year growth in its Biopharma Laboratory Services segment in Q2 2025, with Central Laboratories growing by 8% and Early Development by 20% [3][8] - The Zacks Consensus Estimate for Labcorp's 2025 earnings remains at $16.30, with revenues expected to reach $14.00 billion, indicating a 7.7% increase from 2024 [10] Operational Efficiency - Labcorp is enhancing operational efficiency through initiatives like LaunchPad, which improved the adjusted operating margin by 20 basis points in Q2 [5][6] - The introduction of digital solutions such as the Labcorp Diagnostic Assistant and eClaim Assist aims to streamline workflows and improve billing efficiencies [6] Financial Health - As of Q2 2025, Labcorp had cash and cash equivalents of $793 million, short-term debt of $500 million, and long-term debt of $5.08 billion [7] - The company returned capital to shareholders through $59.9 million in dividends and $200 million in stock repurchases, with a dividend payout ratio of 19% [7] Challenges - Macroeconomic factors, including inflation and geopolitical tensions, have negatively impacted demand for diagnostic testing and drug development services, leading to an 8.1% increase in the cost of revenues year-over-year [9]

Core Insights - Labcorp Holdings Inc. is valued at a market cap of $23 billion and is a leading global provider of comprehensive laboratory services [1] - The company operates through its Diagnostics Laboratories and Biopharma Laboratory Services segments, offering a wide range of testing, specialty diagnostics, and drug development solutions [1][2] Financial Performance - Labcorp's shares have fallen 2.7% from its 52-week high of $283.47 but have risen 5.4% over the past three months, outperforming The Health Care Select Sector SPDR Fund's (XLV) 2.6% gain [3] - Year-to-date, Labcorp's stock is up 20.3%, significantly exceeding XLV's 1.1% decline, and has soared 24.2% over the past 52 weeks compared to XLV's 12.4% decrease [4] - The company reported strong Q2 2025 results with adjusted EPS of $4.35 and revenues of $3.53 billion, surpassing estimates [5] - Growth in Q2 was driven by Diagnostics Laboratories, which grew 8.9% to $2.75 billion, and Biopharma Laboratory Services, which rose 11% to $784.8 million [5] - Full-year 2025 guidance has been raised, with revenue growth now expected at 7.5% - 8.6% and adjusted EPS at $16.05 - $16.50 [5] Market Position and Analyst Sentiment - Despite rival Quest Diagnostics Incorporated (DGX) outperforming Labcorp on a year-to-date basis with a 22.4% increase, Labcorp has outperformed DGX over the past 52 weeks [6] - Analysts maintain a bullish outlook on Labcorp, with a consensus rating of "Strong Buy" from 18 analysts and a mean price target of $295.53, representing a 5.9% premium to current levels [6]